Importance of underlying mechanism and genotype on outcome of sepsis trials

This publication has 24 references indexed in Scilit:

• Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients
  Critical Care Medicine, 2001
• Clinical trial results with antithrombin III in sepsis
  Critical Care Medicine, 2000
• Concluding discussion of the Margaux Conference on Critical Illness: Activation of the coagulation system in critical illnesses
  Critical Care Medicine, 2000
• The sirens' songs of confirmatory sepsis trials
  Critical Care Medicine, 1998
• The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.
  Journal of Clinical Investigation, 1998
• Variation in the Tumor Necrosis Factor- Gene Promoter Region May Be Associated with Death from Meningococcal Disease
  The Journal of Infectious Diseases, 1996
• A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis
  Critical Care Medicine, 1996
• Variation in the TNF-α promoter region associated with susceptibility to cerebral malaria
  Nature, 1994
• An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles.
  The Journal of Experimental Medicine, 1993
• Genetic epidemiology utilizing the adoption method
  Scandinavian Journal of Social Medicine, 1991